Mphasis anticipates Q4 to be its best quarter in the last three years from a QoQ growth perspective, supported by strong TCV wins, improving TCV to revenue conversion, and reiterated margin guidance in the 14.6-16% range.
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
Mphasis Ltd.'s strong order book has positively surprised us along with positive momentum in the banking, financial services and insurance and technology, media and telecommunications vertical which is also in line with industry peers.
But softness in the logistics and travel along with the healthcare vertical warrant some caution. Post Q3 FY25, we have revised downwards our revenue estimates for FY26/FY27 by 2.4%/1.1% with margins and EPS being largely maintained.
We reiterate ‘Hold’ with a slightly lower target price of Rs 3,428, based on the multiple of ~29x Dec’26E EPS (earlier multiple 30.5x). This represents the last three-year average mean + 0.5SD.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU

Blue Star Remains A Solid Long-Term Compounding Story, Says Nirmal Bang Maintaining 'Buy'

BPCL Q1 Review: PL Capital Upgrades The Stock To 'Hold' On Strong Marketing Margins — Check New Target Price


'Buy' Sumitomo Chemical Shares Maintains Nirmal Bang Post Q1 Results — Check Target Price


Suryoday SFB— Well-Positioned For A Valuation Multiple Re-Rating, Says Centrum Post Q1 Result; Maintains 'Buy'
